The potential for QT prolongation and pro-arrhythmia by non-anti- arrhythmic drugs: Clinical and regulatory implications: Report on a Policy Conference of the European Society of Cardiology

Cardiovascular Research

Volumn 47, Issue 2, 2000, Pages 219-233

  Haverkamp, Wilhelm ^a   Breithardt, Günter ^a   Camm, A John ^a   Janse, Michiel J ^a   Rosen, Michael R ^a   Antzelevitch, Charles ^a   Escande, Denis ^a   Franz, Michael ^a   Malik, Marek ^a   Moss, Arthur ^a   Shah, Rashmi ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AJMALINE; ALMOKALANT; AMIODARONE; AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; APRINDINE; AZIMILIDE; BEPRIDIL; BRETYLIUM; CHLORAL HYDRATE; CHLORPROMAZINE; CITALOPRAM; CLOFILIUM; CLOMIPRAMINE; DESIPRAMINE; DISOPYRAMIDE; DOFETILIDE; DOXEPIN; IBUTILIDE; LIDOFLAZINE; NEUROLEPTIC AGENT; PAPAVERINE; POTASSIUM CHANNEL; PRENYLAMINE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SEMATILIDE; SOTALOL; UNINDEXED DRUG; VASODILATOR AGENT;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; EUROPE; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HEART REPOLARIZATION; HUMAN; MEDICAL SOCIETY; PRIORITY JOURNAL; QT INTERVAL; TORSADE DES POINTES;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTI-BACTERIAL AGENTS; ANTIPSYCHOTIC AGENTS; CARDIOLOGY; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; DRUG AND NARCOTIC CONTROL; EUROPE; HUMANS; POTASSIUM CHANNELS; PRODUCT SURVEILLANCE, POSTMARKETING; RESEARCH; SOCIETIES, MEDICAL; TORSADES DE POINTES; VASODILATOR AGENTS;

EID: 0009737358     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(00)00119-X     Document Type: Article

References (81)

1. Selzer A., Wray H.W. Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation. 30:1964;17-26.
2. Roden D.M., Woosley R.L., Primm R.K. Incidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient care. Am Heart J. 111:1986;1088-1093.
3. Kay G.N., Plumb V.J., Arciniegas J.G., Henthorn R.W., Waldo A.L. Torsade de pointes: The long-short initiating sequence and other clinical features: Observations in 32 patients. J Am Coll Cardiol. 2:1983;806-817.
4. Bauman J.L., Bauernfeind R.A., Hoff J.V., Strasberg B., Swiryn S., Rosen K.M. Torsades de pointes due to quinidine: Observations in 31 patients. Am Heart J. 107:1984;425-430.
5. Haverkamp W., Martinez R.A., Hief C., et al. Efficacy and safety of D,L-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest. J Am Coll Cardiol. 30:1997;487-495.
6. Lehmann M.H., Hardy S., Archibald D., Quart B., McNeil D.J. Sex difference in risk of torsade de pointes with D,L-sotalol. Circulation. 94:1996;2535-2541.
7. Hohnloser S.H. Proarrhythmia with class III anti-arrhythmic drugs: Types, risks, and management. Am J Cardiol. 80:1997;82G-89G.
8. Torp-Pederson C., Moller M., Bloch-Thomsen P.E., et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. New Engl J Med. 341:1999;879-911.
9. Stambler B.S., Wood M.A., Ellenbogen K.A., et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation. 94:1996;1613-1621.
10. Zipes DP. Unwitting exposure to risk. Cardiol Rev 1993;1-3.
11. Rosen M.R. Of oocytes and runny noses. Circulation. 94:1996;607-609.
12. Priori S.G. Exploring the hidden danger of non-cardiac drugs. J Cardiovasc Electrophysiol. 9:1998;1114-1116.
13. Ks, absent from undiseased human ventricular myocardium? Cardiovasc Res. 40:1998;433-435.
14. Ks in dog ventricular muscle and Purkinje fiber repolarization. J Physiol. 523:2000;67-81.
15. Ks contributes to the longer action potential of M cells. Circ Res. 76:1995;351-365.
16. Ks. Am J Physiol. 271:1996;H2477-H2489.
17. Ye L., Feng J., Li G.R., Nattel S. Transient outward and delayed rectifier currents in canine atrium: Properties and role of isolation methods. Am J Physiol. 272:1996;H1292-H1301.
18. Tomaselli G.F., Marban E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res. 42:1999;270-283.
19. Antzelevitch C., Sicouri S. Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes. J Am Coll Cardiol. 23:1994;259-277.
20. Viswanathan P.C., Rudy Y. Pause induced early afterdepolarizations in the long QT syndrome: A simulation study. Cardiovasc Res. 42:1999;530-542.
21. Carlsson L., Abrahamsson C., Andersson B., Duker G., Schiller-Lindhardt G. Proarrhythmic effects of class III agent almokalant: Importance of infusion rate. QT dispersion and early after depolarizations. Cardiovasc Res. 27:1993;2186-2193.
22. Burashnikov A., Antzelevitch C. Acceleration-induced action potential prolongation and early afterdepolarizations. J Cardiovasc Electrophysiol. 9:1998;934-948.
23. El-Sherif N., Caref F.B., Yin H., Restivo M. The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome. Tridimensional mapping of activation and recovery patterns. Circ Res. 79:1996;474-492.
24. Surawicz B. Electrophysiological substrate for Torsade de pointes: Dispersion of refractoriness or early afterdepolarizations. J Am Coll Cardiol. 14:1989;172-184.
25. Verduyn S.C., Vos M.A., Van der Zande J., Van der Hulst F.F., Wellens H.J.J. Role of interventricular dispersion of repolarization in acquired torsade-de-pointes arrhythmias: Reversal by magnesium. Cardiovasc Res. 34:1997;453-463.
26. Antzelevitch C., Shimizu W., Yan G.X., et al. The M cell: Its contribution to the ECG and to normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol. 10:1999;1124-1152.
27. Yan G.-X., Shimizu W., Antzelevitch C. Characteristics and distribution of M-cells in arterially perfused canine left ventricular wedge preparations. Circulation. 98:1998;1921-1927.
28. Janse M.J., Capucci A., Coronel R., Fabius M.A.W. Variability of recovery of excitability in the normal canine and the ischaemic porcine heart. Eur Heart J. 6:(Suppl D):1985;41-50.
29. Anyukhovsky E.P., Sosunov E.A., Rosen M.R. Regional differences in electrophysiological properties of epicardium, midmyocardium, and endocardium. In vitro and in vivo correlations. Circulation. 94:1996;1981-1988.
30. Merot J., Charpentier F., Poirier J.M., Coutris J., Weissenburger J. Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: Interactions with acute sotalol. Cardiovasc Res. 44:1999;303-314.
31. + channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol. 273:1997;H2534-H2538.
32. Vitola J., Vukanovic J., Roden D.M. Cisapride-induced Torsade de Pointes. J Cardiovasc Electrophysiol. 9:1998;1109-1113.
33. Roden D.M., Spooner P.M. Inherited long QT syndromes. A paradigm for understanding arrhythmias. J Cardiovasc Electrophysiol. 10:1999;1664-1683.
34. Houltz B., Darpö B., Edvardsson N., et al. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: A prospective study. PACE. 21:1998;1044-1057.
35. Kr potassium channels with HERG and is associated with cardiac arrhythmia. Cell. 97:1999;175-187.
36. Priori S.G., Napolitano C., Schwartz P.J. Low penetrance in the long-QT syndrome: Clinical impact. Circulation. 99:1999;529-533.
37. Roden D.M. Taking the 'idio' out of 'idiosyncratic': Predicting torsades de pointes. PACE. 21:1998;1029-1034.
38. Soffer J., Dreifus L.S., Michelson E.L. Polymorphous ventricular tachycardia associated with normal and long Q-T intervals. Am J Cardiol. 49:1982;2021-2029.
39. Breithardt G., Seipel L., Haerten K. Paradoxic response to disopyramide and quinidine. Z Kardiol. 69:1980;556-561.
40. Wald R.W., Waxman M.B., Colman J.M. Torsade de pointes ventricular tachycardia. A complication of disopyramide shared with quinidine. J Electrocardiol. 14:1981;301-307.
41. Hohnloser S.H., van der Loo A., Baedeker F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: Prospective comparison of sotalol versus quinidine. J Am Coll Cardiol. 26:1995;852-858.
42. Dascal N. The use of Xenopus oocytes for the study of ion channels. Crit Rev Biochem. 22:1987;341-356.
43. Stühmer W., Parekh A.B. Electrophysiological recordings from Xenopus oocytes. Sackmann B., Neher E. Single-channel recordings. 1995;341-356 Plenum Press, New York.
44. Fishman G.I., McDonald T.V. Gene transfer of membrane channel proteins. Zipes D.P., Jalife J. Cardiac electrophysiology. From cell to bedside. 3rd ed. 2000;58-66 Saunders Company, Philadelphia.
45. Lee K.S. Ibutilide, a new compound with potent class III anti-arrhythmic activity, activates a slow inward Na+ current in guinea pig ventricular cells. J Pharmacol Exp Ther. 262:1992;99-108.
46. January C.T., Riddle J.M. Early afterdepolarizations: Mechanism of induction and block. A role for L-type Ca2+ current. Circ Res. 64:1989;977-990.
47. Ks in guinea pig cardiac myocytes. Biochem Biophys Res Commun. 202:1994;265-270.
48. Coronel R., Opthof T., Taggart P., Tygat J., Veldkamp M. Differential electrophysiology of repolarization from clone to clinic. Cardiovasc Res. 33:1997;503-517.
49. Drici M.D., Burklow T.R., Haridasse V., Glazer R.I., Woosley R.L. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation. 94:1996;1471-1474.
50. Pinney S.P., Koller B.S., Franz M.R., Woosley R.L. Terfenadine increases the QT interval in isolated guinea pig heart. J Cardiovasc Pharmacol. 25:1995;30-34.
51. Eckardt L., Haverkamp W., Mertens H., et al. Drug related torsade de pointes in the isolated rabbit heart: Comparison of clofilium, D,L-sotalol and erythromycin. J Cardiovasc Pharmacol. 32:1998;425-434.
52. Zabel M., Hohnloser S.H., Behrens S., et al. Electrophysiologic features of torsade de pointes: Insights from a new rabbit heart model. J Cardiovasc Electrophysiol. 8:1997;1148-1158.
53. Johna R., Mertens H., Haverkamp W., et al. Clofilium in the isolated perfused rabbit heart: A new model to study proarrhythmia by class III anti-arrhythmic drugs. Basic Res Cardiol. 93:1998;127-135.
54. Sosunov E.A., Gainullin R.Z., Danilo P.J., et al. Electrophysiological effects of LU111995 on canine hearts: In vivo and in vitro studies. J Pharmacol Exp Ther. 290:1999;146-152.
55. Carlsson L., Amos G.J., Andersson B., et al. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: Implications for proarrhythmic potential? J Pharmacol Exp Ther. 282:1997;220-227.
56. Detweiler D.K. Electrocardiography in toxicological studies. Sipes I.G., McQueen C.A., Gandolfi A.J. Comprehensive toxicology. 1977;95-114 Pergamon Press, New York.
57. Carlsson L., Almgren O., Duker G. QTU-prolongation and torsades de pointes induced by putative class III anti-arrhythmic agents in the rabbit: Etiology and interventions. J Cardiovasc Pharmacol. 16:1990;276-285.
58. Chezalviel-Guilbert F., Davy J.M., Poirier J.M., Weissenburger J. Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrythmic effects in a canine model of torsade de pointes. J Am Coll Cardiol. 26:1995;787-792.
59. Weissenburger J., Davy J.M., Chezalviel F., et al. Arrhythmogenic activities of anti-arrhythmic drugs in conscious hypokalemic dogs with atrioventricular block: Comparison between quinidine, lidocaine, flecainide, propranolol and sotalol. J Pharmacol Exp Ther. 259:1991;871-883.
60. Vos M.A., Verduyn S.C., Gorgels A.P., Lipcsei G.C., Wellens H.J.J. Reproducible induction of early afterdepolarizations and torsade de pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block. Circulation. 91:1995;864-872.
61. Vos M.A., de Groot S.H.M., Verduyn S.C., et al. Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling. Circulation. 98:1998;1125-1135.
62. Points to consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. December, 1997;The European Agency for the Evaluation of Medicinal Products.
63. Moss A.J. Measurement of the QT interval and the risk associated with QTc interval prolongation: A review. Am J Cardiol. 72:1993;22B-23B.
64. Ahnve S. Correction of the QT interval for heart rate: Review of different formulas and the use of Bazett's formula in myocardial infarction. Am Heart J. 109:1985;568-574.
65. Sagie A., Larson M.G., Goldberg R.J., Bengtson J.R., Levy D. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol. 70:1992;797-801.
66. Hnatkova K., Malik M. 'Optimum' formulae for heart rate correction of the QT interval. PACE. 22:1999;1683-1687.
67. Honig P.K., Wortham D.C., Zamani K., Conner D.P., Mullin J.C., Cantilena L.R. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. J Am Med Assoc. 269:1993;1513-1518.
68. Bauman J.L., Sanoski C.A., Chan L.N. Pharmacokinetic and pharmacodynamic drug interactions with anti-arrhythmic agents. Cardiol Rev. 5:1997;292-304.
69. Pratt C.M., Ruberg S., Morganroth J., et al. Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: Distinguishing a drug effect from spontaneous variability. Am Heart J. 131:1996;472-480.
70. Cavuto N.J., Woosley R.L., Sale M., Bates D.W., Leape L.L. Pharmacies and prevention of potentially fatal drug interactions. J Am Med Assoc. 275:1996;1086-1087.
71. Thompson D., Oster G. Use of terfenadine and contraindicated drugs. J Am Med Assoc. 275:1996;1339-1341.
72. Anonymous. Janssen propulsid prescribing for inpatients questioned in three studies. F-D-C Report The Pink Sheet 1998;60:26.
73. Kr. Circulation. 93:1996;407-411.
74. Hondeghem L.M., Snyders D.J. Class III anti-arrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation. 81:1990;686-690.
75. Makkar R.R., Fromm B.S., Steinman R.T., Leissner M.D., Lehmann M.H. Female gender as a risk factor for torsade de pointes associated with cardiovascular drugs. J Am Med Assoc. 270:1993;2547-2590.
76. Liu X.-K., Katchman A., Drici M.-D., et al. Gender differences in the cycle-length dependent QT and potassium currents in rabbits. J Pharm Exp Ther. 285:1998;672-679.
77. Vermeulen J.T., McGuire M.A., Opthof T., Coronel R., et al. Triggered activity and automaticity in ventricular trabeculae of failing human and rabbit hearts. Cardiovasc Res. 28:1994;1547-1554.
78. Roy M., Dumaine R., Brown A.M. HERG, a primary human ventricular target of the non-sedating antihistamine terfenadine. Circulation. 94:1996;817-823.
79. Hirao H., Shimizu W., Kurita T., et al. Frequency-dependent electrophysiological properties of ventricular repolarization in patients with congenital long QT syndrome. J Am Coll Cardiol. 28:1996;1269-1277.
80. Sun Z.-H., Swan H., Viitasalo M., Toivonen L. Effects of epinephrine and phenylephrine of QT interval dispersion in congenital long QT syndrome. J Am Coll Cardiol. 31:1998;1400-1405.
81. Shimizu W., Antzelevitch C. Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome. Effects of beta-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes. Circulation. 98:1998;2314-2322.